- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05022771
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
December 6, 2022 updated by: Pulmongene Ltd.
A Phase 1A, First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 in Healthy Volunteers
This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers.
PMG1015 is a monoclonal antibody, being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF).
This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after Single ascending doses (SAD).
Study Overview
Status
Completed
Conditions
Detailed Description
Participants will be enrolled and randomized into 1 of 7 cohorts in a double-blind manner.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ning Wu
- Phone Number: +86 18228071008
- Email: ning_wu@pulmongene.com
Study Contact Backup
- Name: Wenxiu Qu
- Phone Number: +86 18940257027
- Email: wenxiu_qu@pulmongene.com
Study Locations
-
-
Queensland
-
Herston, Queensland, Australia, 4006
- Q-Pharm Pty Ltd, Clive Berghofer Cancer Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or non-pregnant, non-lactating female volunteers, between 18 and 60 years of age, inclusive at the time of informed consent.
- Body mass index (BMI) between 17.5 and 32.0 kg/m2 (inclusive) and body weight between 50 and 100 kg for males and between 45 and 100 kg for females.
- No clinically significant clinical laboratory values (Hematology, coagulation, biochemistry and urinalysis) at the discretion of the PI.
- Females of child bearing potential must use an acceptable, highly effective double contraception and have a negative pregnancy test at Screening and Day-1.
- Documented evidence of surgical sterilization at least 6 months prior to screening for women or vasectomy at least 90 days prior to screening.
- Women not of child bearing potential must be menopausal for >/= 12 months.
- Males must not donate sperms for at least 90 days after PMG1015 administration.
Exclusion Criteria:
- History or evidence of clinically significant condition, including but not limited to any cardiovascular, gastrointestinal, endocrinologic, hematologic, psychiatric, renal disease, musculoskeletal, infectious, or neurological condition or any chronic medical condition and/or other major disease, as determined by the PI.
- A PR < 40 or > 100 beats per minute, mean systolic blood pressure (SBP) > 140 mmHg, or mean diastolic blood pressure (DBP) > 95 mmHg .
- A mean corrected QT interval using Fridericia's formula (QTcF) interval at Screening > 450 ms in males and > 470 ms in females. If the mean QTcF exceeds these limits, one additional triplicate ECG will be performed.
- Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, in the judgment of the PI, may interfere with the interpretation of QTc-interval changes, including abnormal ST-T wave morphology or left ventricular hypertrophy.
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or creatinine > 1.5 × the upper limit of the normal range (ULN) or total bilirubin or lymphocyte counts > ULN.
- Participants with a positive toxicology screening panel or alcohol breath test on Screening/Day-1.
- Participants with a history of substance abuse or dependency or history of recreational IV drug use over the last 2 years.
- Plasma donation/Blood donation or significant blood loss within 60 days prior to the first IP administration.
- Use of any IP (including other investigational mAb products) or investigational medical device within 30 days prior to Screening or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to screening.
- Major surgery (general anesthetic) within 3 months or minor surgery (local anesthetic) within 1 month prior to IP administration, or planned surgery during the study period, which is determined by the PI to be clinically relevant.
- Fever or symptomatic bacterial or viral infection.
- Participants who have received live vaccines or attenuated vaccines within 1 month before dosing.
- Participants with any active malignancy or history of malignancy within 5 years prior to enrolment.
- Use of any other prescription medications.
- History of anaphylaxis, allergic reactions to the excipients of IP, asthma.
- Positive blood screen for HIV1/2 antibody, Hepatitis B surface antigen, hepatitis C virus, or syphilis at screening.
- Participants with an inability to tolerate venous access.
- Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period.
- An employee of Pulmongene or Novotech (Australia) Pty Ltd.
- Participant is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and while resident at the CRU.
- Any other condition or finding that in the opinion of the PI or designee would put the participant or study conduct at risk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Ascending Doses Cohort 1a
Subjects will receive either Dose level 1 of PMG1015 or Placebo
|
Placebo to match
Dose level 1 of PMG1015
Other Names:
|
Experimental: Single Ascending Doses Cohort 1b
Subjects will receive either Dose level 2 of PMG1015 or Placebo
|
Placebo to match
Dose level 2 of PMG1015
Other Names:
|
Experimental: Single Ascending Doses Cohort 1c
Subjects will receive either Dose level 3 of PMG1015 or Placebo
|
Placebo to match
Dose level 3 of PMG1015
Other Names:
|
Experimental: Single Ascending Doses Cohort 1d
Subjects will receive either Dose level 4 of PMG1015 or Placebo
|
Placebo to match
Dose level 4 of PMG1015
Other Names:
|
Experimental: Single Ascending Doses Cohort 1e
Subjects will receive either Dose level 5 of PMG1015 or Placebo
|
Placebo to match
Dose level 5 of PMG1015
Other Names:
|
Experimental: Single Ascending Doses Cohort 1f
Subjects will receive either Dose level 6 of PMG1015 or Placebo
|
Placebo to match
Dose level 6 of PMG1015
Other Names:
|
Experimental: Single Ascending Doses Cohort 1g
Subjects will receive either Dose level 7 of PMG1015 or Placebo
|
Placebo to match
Dose level 7 of PMG1015
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of Treatment-emergent adverse events (TEAEs)
Time Frame: Day 1-Day 85
|
An Adverse Event (AE) is any event, side-effect or any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
TEAEs are AEs that occur following the start of treatment.
|
Day 1-Day 85
|
The severity of Treatment-emergent adverse events (TEAEs)
Time Frame: Day 1-Day 85
|
TEAEs are AEs that occur following the start of treatment.
|
Day 1-Day 85
|
The incidence of Serious adverse events (SAEs)
Time Frame: Day 1-Day 85
|
A serious adverse event (SAE) is defined as an AE occurring during any study phase and at any dose of IP (active or placebo) that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect.
|
Day 1-Day 85
|
The severity of Serious adverse events (SAEs)
Time Frame: Day 1- Day 85
|
A serious adverse event (SAE) is defined as an AE occurring during any study phase and at any dose of IP (active or placebo) that results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; results in congenital anomaly/birth defect.
|
Day 1- Day 85
|
Number of participants with abnormally clinical vital signs
Time Frame: Day 1- Day 85
|
Vital signs include pulse rate (PR), blood pressure (BP), respiratory rate (RR) and tympanic temperature (T)
|
Day 1- Day 85
|
Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters
Time Frame: Day 1-Day 85.
|
All ECG tracings will be reviewed by the PI or designee and assessed for clinical significance.
|
Day 1-Day 85.
|
Number of participants with abnormal clinically significant clinical laboratory results
Time Frame: Day 1- Day 85
|
Clinical laboratory test include hematology, coagulation, biochemistry, and urinalysis.
|
Day 1- Day 85
|
MTD of PMG1015 in healthy participants
Time Frame: Day 1- Day 85
|
Maximum tolerated dose of PMG1015 in healthy participants
|
Day 1- Day 85
|
Number of patients with abnormal clinically significant results from physical examination
Time Frame: Day 1-Day 85
|
Complete physical examination include, general appearance, head, eyes, ears, nose, throat, dentition, thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.
|
Day 1-Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the serum-concentration time curve (AUC) from time zero (from the start of infusion time) to the last time point with measurable analyte concentration (AUC0-t)
Time Frame: Day 1-Day 85.
|
Area under the plasma concentration versus time curve (AUC) from time 0 to time of last quantifiable concentration
|
Day 1-Day 85.
|
AUC from time zero to infinity (AUC0-∞)
Time Frame: Day 1-Day 85.
|
Area under the plasma concentration versus time curve (AUC) from time 0 (from the start of infusion) extrapolated to infinity
|
Day 1-Day 85.
|
To determine %AUCexp
Time Frame: Day 1-Day 85.
|
The percentage of the AUC that has been extrapolated beyond the last observed data point
|
Day 1-Day 85.
|
To determine Cmax
Time Frame: Day 1-Day 85.
|
Maximum observed serum PMG1015 concentration
|
Day 1-Day 85.
|
To determine Tmax, derived from serum concentration of each dose of PMG1015
Time Frame: Day 1-Day 85.
|
Time to maximum observed concentration
|
Day 1-Day 85.
|
To determine t1/2
Time Frame: Day 1-Day 85.
|
Terminal elimination half life summarized by dosing regimen
|
Day 1-Day 85.
|
Apparent total body clearance (CL)
Time Frame: Day 1-Day 85.
|
CL is the measure of the rate at which a drug is metabolized or eliminated by normal biological processes
|
Day 1-Day 85.
|
Apparent volume of distribution during the terminal phase (Vz)
Time Frame: Day 1-Day 85.
|
Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
|
Day 1-Day 85.
|
Apparent terminal elimination rate constant (λz or kel)
Time Frame: Day 1-Day 85.
|
λz is calculated using log-linear regression of the terminal portions of the plasma concentrations versus time curves.
|
Day 1-Day 85.
|
Levels of ADA
Time Frame: Day 1-Day 85
|
Anti-drug antibody levels in blood
|
Day 1-Day 85
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard Friend, Nucleus Network
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 14, 2021
Primary Completion (Actual)
August 10, 2022
Study Completion (Actual)
August 10, 2022
Study Registration Dates
First Submitted
August 20, 2021
First Submitted That Met QC Criteria
August 20, 2021
First Posted (Actual)
August 26, 2021
Study Record Updates
Last Update Posted (Estimate)
December 8, 2022
Last Update Submitted That Met QC Criteria
December 6, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMG1015-AUS-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States